Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07JAN
|
||||
| Former ID |
DIB020928
|
||||
| Drug Name |
SCH 206272
|
||||
| Synonyms |
SCH-206272
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C33H41Cl4N5O4
|
||||
| InChI |
InChI=1S/C33H41Cl4N5O4/c1-38-31(43)18-22-5-4-11-42(33(22)45)26-8-12-41(13-9-26)14-10-27(21-6-7-28(36)29(37)17-21)30(39-46-3)20-40(2)32(44)23-15-24(34)19-25(35)16-23/h6-7,15-17,19,22,26-27H,4-5,8-14,18,20H2,1-3H3,(H,38,43)/b39-30+/t22-,27-/m1/s1
|
||||
| InChIKey |
UITMLIVWRRGLLR-SUFYPKAWSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Nigral tachykinin NK(3) receptor | Target Info | Antagonist | [2] | |
| NK-2 receptor | Target Info | Antagonist | [2] | ||
| Substance-P receptor | Target Info | Antagonist | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Measles | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Reactome | G alpha (q) signalling eventsR-HSA-416476:G alpha (q) signalling eventsR-HSA-416476:G alpha (q) signalling events | ||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR downstream signalingWP706:SIDS Susceptibility Pathways | |||||
| Spinal Cord Injury | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2106). | ||||
| REF 2 | SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.